Parkinson's is expected to double in the next 25 years. WH spoke to experts to hear why this might happen and what we can do ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Parkinson's disease affects 8.5 million people globally, with symptoms including tremors, slow movement, and muscle stiffness ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a ...

Learn more about whether Amneal Pharmaceuticals, Inc. or HUTCHMED (China) Limited is a better investment based on AAII's A+ ...

Seventeen patients with Parkinsonism were admitted to this study. All had been referred to us by their physicians, after treatment with several standard medications for relief of this disorder ...

A new study published in Cell Reports reveals a breakthrough discovery linking genetic variants in the gene ITSN1 to a ...

Good day, and welcome to the Legend Biotech Fourth Quarter and Full-Year 2024 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a ...

Scientists have identified a rare genetic mutation in ITSN1 that increases the risk of Parkinson’s disease by up to tenfold, ...